Monica Roy

Monica Roy has extensive experience in the field of ophthalmology and clinical development. Monica currently holds the position of Vice President of Clinical Development in Ophthalmology at EyePoint Pharmaceuticals, a role they began in 2022. Prior to this, Monica worked as the Vice President of Clinical Development in Ophthalmology CRISPR Gene Editing at Editas Medicine in 2021. From 2018 to 2021, they were the Senior Director of Program Development in Ophthalmology Gene Therapy at REGENXBIO Inc. Monica also held the position of Director of Global Clinical Development in Lifitegrast/Xiidra, Ophthalmology at Shire from 2014 to 2018. Before their roles in industry, they worked as a Global Clinical Lead at Alcon from 2012 to 2014. Monica's career began with positions as Clinical Instructor/Attending at The Ohio State University from 2007 to 2012 and in Medical Affairs at Johnson & Johnson in 2008. Prior to this, they gained experience in clinical trial research at The Wexner Medical Center from 2003 to 2007 and The Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute from 2003 to 2005.

Monica Roy has received an OD, MPH, FAAO degree from The Ohio State University College of Medicine. Monica has also completed a Post Doc Residency in Anterior Seg/Cornea at The Ohio State University.